Astellas Pharma. has been granted a patent for a pharmaceutical composition that enhances the solubility and oral absorbability of enzalutamide. The composition includes enzalutamide and polyvinyl alcohol, specifically with a saponification degree of 55-85 mol% and a polymerization degree of 100-500. GlobalData’s report on Astellas Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Astellas Pharma, Cancer treatment biomarkers was a key innovation area identified from patents. Astellas Pharma's grant share as of June 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.
Improved oral formulation of enzalutamide with polyvinyl alcohol
The granted patent US12036315B2 outlines a pharmaceutical composition designed for oral administration that includes enzalutamide and polyvinyl alcohol. The polyvinyl alcohol specified in the claims has a saponification degree ranging from 55 mol% to less than 85 mol% and a polymerization degree between 100 and 500. The composition may also include a solid dispersion of enzalutamide and polyvinyl alcohol, as well as additional components such as substances that can act as hydrogen bond acceptors, exemplified by polyvinyl pyrrolidone or copolyvidone. Furthermore, the composition can incorporate disintegrants or co-disintegrants, with specific examples including potassium chloride, sodium chloride, magnesium chloride, and crospovidone.
The patent also details methods for producing the pharmaceutical composition, emphasizing the preparation of solid dispersions through techniques such as hot melt extrusion or solvent methods. The claims specify that the pharmaceutical composition can take the form of a tablet and that enzalutamide may be in an amorphous state. Additional claims refine the characteristics of polyvinyl alcohol, indicating preferred saponification degrees of 63 mol% to less than 82 mol% or 66 mol% to less than 80 mol%. Overall, the patent presents a comprehensive formulation and production method for a novel oral pharmaceutical composition containing enzalutamide.
To know more about GlobalData’s detailed insights on Astellas Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
